Virtual event with a local partner hub in Berlin
Register for IAS 2021 today and join thousands of HIV professionals at the world’s most influential virtual meeting on HIV research.
Early registration closes on 31 March 2021.
Royal Melbourne Hospital, Australia
Emerging and re-emerging STIs in the genomic era
Alfred Health, Australia
Antiretroviral therapy: Time to change the paradigm?
National Institute for Communicable Diseases, South Africa
HIV vaccines and immunotherapy: Quo vadis?
African Sex Workers Alliance, Kenya
Decriminalization of sex work and providing for good health outcomes for sex workers
Taipei City Hospital, Taiwan (PoC)
Sexualized drug use and HIV infection
| ON-DEMAND: Oral Abstracts |
ON-DEMAND: E-posters |
Sunday 18 July |
Monday 19 July |
Tuesday 20 July |
Wednesday 21 July |
IAS Channel | Berlin Programme | |
|---|---|---|---|---|---|---|---|---|
| 08:00 | Satellite Sessions | |||||||
| 09:00 | Opening | Parallel Sessions | Parallel Sessions | |||||
| 10:00 | Parallel Sessions | Parallel Sessions | ||||||
| 11:00 | Satellite Sessions | |||||||
| 12:00 | ||||||||
| 13:00 | Prime Sessions | Prime Sessions | Prime Sessions | Prime Sessions | ||||
| 14:00 | Parallel Sessions | Parallel Sessions | Parallel Sessions | Parallel Sessions | ||||
| 15:00 | ||||||||
| 16:00 | Satellite Sessions | Closing | ||||||
| 17:00 | Satellite Sessions | Satellite Sessions | ||||||
| 18:00 | Prime Sessions | Prime Sessions | Prime Sessions | |||||
| 19:00 | Satellite Sessions | Satellite Sessions | Satellite Sessions | |||||
| 20:00 | ||||||||
| 21:00 |
IAS – The International AIDS Society – leads collective action on every front of the global HIV response through its membership base, scientific authority and convening power.
Founded in 1988, the IAS is the world’s largest association of HIV professionals, with members in more than 170 countries. Working with its members, the IAS advocates and drives urgent action to reduce the impact of HIV. The IAS is also the steward of the world’s most prestigious HIV conferences: the International AIDS Conference, the IAS Conference on HIV Science, and the HIV Research for Prevention Conference. In light of the SARS-CoV-2 pandemic, IAS also convened two abstract driven COVID-19 conferences, in July 2020 and February 2021.
Prof Adeeba Kamarulzaman of Malaysia became the first Asian President of IAS – the International AIDS Society – on 11 July 2020 when she began her two–year term. Prof Kamarulzaman is an Adjunct Associate Professor at Yale University, USA, and chairs the Malaysian AIDS Foundation, a trust that raises funds for HIV- related programmes. In 1997, Prof Kamarulzaman established the Infectious Diseases Unit at the University of Malaya Medical Centre and, in 2008, the Centre of Excellence for Research in AIDS (CERiA) at the same university. As convener of the Malaysian Harm Reduction Working Group of the Malaysian AIDS Council, she successfully advocated for the implementation of harm reduction measures to tackle HIV among people who inject drugs in Malaysia. She was the President of the Malaysian AIDS Council from 2006 to 2010. In 2015, she was awarded an Honorary Doctor of Laws by her alma mater, Monash University, Australia, for her contributions to medicine and as a health advocate.
Professor Hendrik Streeck is the Director of the Institute of Virology and Professor of HIV Research at the University of Bonn, Germany. He completed his medical training in Berlin in 2006 and received his PhD from Friedrich-Wilhelm University in Bonn in 2007. After completing his postdoctoral fellowship at the Partners AIDS Research Center, he was Assistant Professor at the Ragon Institute of MGH, MIT and Harvard and assistant immunologist at the Massachusetts General Hospital. In 2012, he was recruited as the Chief of the Cellular Immunology Section of the U.S. Military HIV Research Program and adjunct Assistant Professor of Emerging Infectious Diseases at the Uniformed Services University of the Health Sciences. In March 2015, he took the chair of the Institute for HIV Research, but remains visiting scientist at the Military HIV Research Program on HIV vaccine and cure research. Currently, he leads the largest systematic study to understand the feasibility of conducting a Phase 3 HIV vaccine trial in Europe and to understand the epidemic of sexually transmitted infections. As a result of the study, the European HIV & STI prevention network was established in January 2019.
Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases. Dr. Fauci has been a key advisor to six Presidents and their administrations on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. As an HIV/AIDS researcher he has been involved in the scientific effort since AIDS was recognized in 1981, conducting pivotal studies that underpin the current understanding of the disease and efforts to develop therapies and tools of prevention. Dr. Fauci was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has helped save millions of lives throughout the developing world.
Dr. Fauci is the long-time chief of the NIAID Laboratory of Immunoregulation. He has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise mechanisms whereby immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener’s granulomatosis), and lymphomatoid granulomatosis.
Dr. Fauci has made seminal contributions to the understanding of how HIV destroys the body’s defenses leading to its susceptibility to deadly infections. Further, he has been instrumental in developing highly effective strategies for the therapy of patients living with HIV/AIDS, as well as for a vaccine to prevent HIV infection. He continues to devote much of his research time to identifying the nature of the immunopathogenic mechanisms of HIV infection and the scope of the body’s immune responses to HIV.
Dr. Fauci is a member of the US National Academy of Sciences and the US National Academy of Medicine, and is the recipient of numerous prestigious awards for his scientific and global health accomplishments, including the National Medal of Science, the Robert Koch Medal, the Mary Woodard Lasker Award for Public Service, the Prince Mahidol Prize, The Gairdner Canada Award for Global Health, and the Presidential Medal of Freedom. He has been awarded 45 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,300 scientific publications, including several major textbooks
Dr Douek is a tenured senior investigator and the Chief of the Human Immunology Section, Vaccine Research Center, NIAID, National Institutes of Health (NIH), Bethesda, USA. He studied medicine at the Universities of Oxford and London and practised internal medicine before pursuing a PhD in immunology at the University of London. He was appointed to the NIH Vaccine Research Center in November 2000.
His laboratory, the Human Immunology Section, studies the processes that determine the course of human diseases in which the immune system, particularly its T-cell arm, plays a central role in their pathogenesis and outcome. He aims to use the knowledge gained to initiate clinical studies of new therapeutic and vaccine approaches.
Dr Douek is widely published in the field of human immunology, having made significant discoveries in thymic function, immune repertoire diversity, T-cell mediated immunity, mucosal immunology, innate immunity and hematopoietic progenitor cell transplantation. He has published more than 300 papers, has an h-index of 100 and is among the 1% most cited scientists in their field. Currently, the main focus of his lab is the pathogenesis of HIV infection, the role of the microbiome in modulating systemic inflammation, and host genetic factors that predispose to or protect from infectious disease.
He sits on numerous scientific advisory boards and journal editorial boards. Dr Douek received the World AIDS Day Award in 2007 and the NIH Director’s Award in 2008. Scientific American recognized him as one of the world’s top 50 scientists in 2005 and he was placed among the 2012 POZ 100 for his significant contributions to accelerating the end of AIDS.
Renzo Guinto, MD, DrPH, is one of the staunchest voices for the new field of planetary health. Renzo is the Chief Planetary Doctor of PH Lab, a “glo-cal think-and-do tank” for advancing the health of both people and the planet. He is also Associate Professor of the Practice of Global Public Health and Inaugural Director of the Planetary and Global Health Program of the St. Luke’s Medical Center College of Medicine in the Philippines.
Renzo is an Obama Foundation Asia-Pacific Leader, Aspen Institute New Voices Fellow and Climate Reality Leader (under the initiative of former US Vice President Al Gore). He is a member of several high-level groups, including: Lancet–Chatham House Commission on Improving Population Health post COVID-19 (University of Cambridge); Lancet One Health Commission (University of Oslo); Advisory Council of Global Health 50/50 (University College London); Advisory Board of Climate Cares (Imperial College London); Editorial Advisory Board of The Lancet Planetary Health; and Forum on Climate Change and Health of the World Innovation Summit for Health (Qatar Foundation). He has served as consultant for various organizations, including: World Health Organization; World Bank; USAID; International Organization for Migration; Health Care Without Harm; Philippine Department of Health; Chilean Ministry of Health; and Institute of Tropical Medicine in Antwerp, Belgium.
Renzo obtained his Doctor of Public Health from Harvard University and Doctor of Medicine from the University of the Philippines Manila. In 2020, Tatler Magazine included him in its Gen.T List of 400 leaders of tomorrow who are shaping Asia’s future. He has lectured in nearly 50 countries and published more than 100 articles in scientific journals, books and popular media; he has also directed and produced short films that communicate the message of planetary healing.
Professor Jenny Hoy is an infectious diseases physician and Professor Director of HIV Medicine at Alfred Health and Monash University. She graduated from Monash University and trained in infectious diseases at Fairfield Infectious Diseases in Melbourne, Australia. She led the HIV clinical research effort at Fairfield Hospital, participating in the evaluation of new antiretrovirals and new approaches to opportunistic infection prevention and management. The HIV service moved from Fairfield Hospital to Alfred Hospital in 1996 when Fairfield Hospital closed. Over the next 25 years, Professor Hoy has remained involved in care of people living with HIV and research, particularly research to aid the understanding of the pathogenesis, prevention and management of co-morbidities associated with ageing and HIV. She is actively engaged in HIV education for undergraduate, infectious diseases trainees and general practitioners. She has published widely, with over 300 publications, monographs and book chapters. She was a member of the Australian Antiretroviral Guidelines Panel for 22 years before joining the IAS-USA Antiretroviral Guidelines panel in 2012. Professor Hoy is passionate about ensuring quality of care for people with HIV and quality of life experienced by people with HIV.
Lynn Morris is a scientist who heads the HIV Virology section at the National Institute for Communicable Diseases (NICD) in Johannesburg, South Africa. She holds a joint appointment at the University of the Witwatersrand, where she is Research Professor and Director of the Antibody Immunity Research Unit. Over the past 20 years, she has made significant contributions to understanding the antibody response to HIV. With collaborators from Centre for the AIDS Programme of Research in South Africa (CAPRISA) and the National Institutes of Health (NIH) Vaccine Research Centre, she discovered the CAP256-VRC26.25 monoclonal antibody that is undergoing clinical testing. Her laboratory is responsible for conducting neutralizing antibody assays for HIV clinical trials, including the Antibody Mediated Prevention (AMP) trial, providing the proof of principle that VRC01 can prevent HIV infection. Lynn has been recognized through several awards. She has published over 270 papers, holds a current author H-Index of 61 and has featured in the Web of Science list of most highly cited researchers in 2015-2019.
Phelister Abdalla is the National Coordinator of the Kenya Sex Workers Alliance. She is a co-founder of the African Sex Workers Alliance (ASWA) and a pioneer of sex workers’ movements in Africa. She is on the front line of creating awareness and advocating for the rights of sex workers at national, regional and global levels; this includes lobbying and advocating for policy reform and leading the process of decriminalization of sex work in Kenya. She is known for her articulation in addressing critical issues, such as stigma and discrimination, violence faced by sex workers, empowerment of the community of sex workers, inclusion of the sex workers’ agenda across the country and Africa, and meaningfully involving communities in all aspects of programming and implementation.
Dr Stephane Wen-Wei Ku completed his medical degree at National Taiwan University in 2008 and specialist training in internal medicine and infectious diseases at Taipei Veterans General Hospital in 2013. He is currently working as the Director of the Division of Infectious Diseases at Taipei City Hospital Renai Branch and clinical researcher with the TREAT Asia Network at Taipei Veterans General Hospital. Dr Ku’s research interests include HIV and sexually transmitted infections, chemsex and sexual well-being of the LGBT community. He has been actively involved in PrEP implementation in Taiwan. Dr Ku serves as a council member of the Taiwan AIDS Society and Chairman of HIV Education And Research Taiwan.
Professor Deborah Williamson is a clinical and public health microbiologist, Professor and Director of Microbiology at the Royal Melbourne Hospital and the Doherty Institute, Deputy Director of the Microbiological Diagnostic Unit Public Health Laboratory, and a laboratory head in the Department of Microbiology and Immunology at the University of Melbourne. She is an NHMRC Investigator Grant recipient, received a L’Oreal-UNESCO Women in Science Fellowship in 2017, and was awarded the Australasian Society for Infectious Diseases Frank Fenner Award in 2020.
